🟢 Roche is trading 4.05% up today after positive interim Phase III Tam-Peli results

Roche is trading 4.05% up now at $54.86 after collaborator MediLink reported positive interim Phase III TAISHAN-302 results on September 13, 2026.

• Tam-Peli reduced the risk of death by 54% versus topotecan in relapsed small-cell lung cancer.
• Median overall survival was 13.3 versus 9.4 months; progression-free survival and response rates also improved.
• The results supported the company-specific rally.